Evidence map›Paper›PMID 41866871›Full record

ArticleSmall (Weinheim an der Bergstrasse, Germany)2026

A Targeted Nanozyme for STING Activation Improves BiTEs Therapy Outcomes in Colorectal Cancer.

Min Mu, Bo Chen, Hui Li, Chenqian Feng, Susu Xiao, Rangrang Fan, Aiping Tong, Nianyong Chen, Gang Guo

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Small (Weinheim an der Bergstrasse, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Min MuDepartment of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, Department of Radiation Oncology and Department of Head and Neck Oncology, West China Hospital, Sichuan University, Chengdu, China.ORCID https://orcid.org/0009-0001-7924-4598
Bo ChenDepartment of Pharmacy, Chongqing University Cancer Hospital, Chongqing, China.
Hui LiDepartment of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, Department of Radiation Oncology and Department of Head and Neck Oncology, West China Hospital, Sichuan University, Chengdu, China.
Chenqian FengDepartment of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, Department of Radiation Oncology and Department of Head and Neck Oncology, West China Hospital, Sichuan University, Chengdu, China.
Susu XiaoDepartment of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, Department of Radiation Oncology and Department of Head and Neck Oncology, West China Hospital, Sichuan University, Chengdu, China.
Rangrang FanDepartment of Neurosurgery, West China Hospital, Sichuan University, Chengdu, China.
Aiping TongDepartment of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, Department of Radiation Oncology and Department of Head and Neck Oncology, West China Hospital, Sichuan University, Chengdu, China.
Nianyong ChenDepartment of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, Department of Radiation Oncology and Department of Head and Neck Oncology, West China Hospital, Sichuan University, Chengdu, China.
Gang GuoDepartment of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, Department of Radiation Oncology and Department of Head and Neck Oncology, West China Hospital, Sichuan University, Chengdu, China.ORCID https://orcid.org/0000-0002-4440-6366

Funding

China Postdoctoral Science Foundation 2024M762225National Natural Science Foundation of China 31971308National Natural Science Foundation of China 82573406Postdoctor Research Fund of West China Hospital, Sichuan University 2025HXBH035
6 · The paper itself

Abstract

Colorectal cancer (CRC) remains a leading cause of cancer-related mortality worldwide, with limited efficacy of conventional therapies due to immunosuppressive tumor microenvironments and high recurrence. While bispecific T-cell engagers (BiTEs) show promise by engaging T cells against tumors, their clinical translation is hindered by poor stability, on-target off-tumor effect, and systemic toxicity. Herein, we develop a tumor-targeted nanozyme (MnO

Indexed as

Colorectal NeoplasmsMembrane ProteinsNanoparticlesAnimalsCell Line, TumorcGAS-STING Signaling PathwayDNAHumansImmunotherapyManganese CompoundsMiceOxidesSTING ProteinT-LymphocytesTreatment OutcomeTumor MicroenvironmentDNAManganese CompoundsMembrane ProteinsOxidesSTING1 protein, humanSTING ProteinBiTEcolorectal cancerimmunotherapynanozymeSTING

Identifiers

PMID41866871
PMCPMC13351494

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.